Research
Hormonal
54.6% of patients in the orforglipron 36-mg group achieved a weight reduction of 10% or more, compared to 12.9% in the placebo group.
A significant proportion of obese adults may achieve clinically meaningful weight loss with orforglipron.
StrongSupportsmedium confidence
Among the patients in the orforglipron 36-mg group, 54.6% had a reduction of 10% or more, as compared with 12.9% of the patients in the placebo group.
Why this rating
Based on a phase 3 randomized controlled trial design.
Source
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Sean Wharton et al. · New England Journal of Medicine · 2025
rct · n=3127Cited 69×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →